Cited by 35Click Chemistry and ApplicationsRedox biology and oxidative stressProtein Degradation and Inhibitors

Chemoproteomics-Enabled Covalent Ligand Screening Reveals a Thioredoxin-Caspase 3 Interaction Disruptor That Impairs Breast Cancer Pathogenicity

Open access
Anderson, Kimberly E., To, Milton, Olzmann, James A., Nomura, Daniel K.·2017·ACS Chemical Biology

Abstract

Covalent ligand discovery is a promising strategy to develop small-molecule effectors against therapeutic targets. Recent studies have shown that dichlorotriazines are promising reactive scaffolds that preferentially react with lysines. Here, we have synthesized a series of dichlorotriazine-based covalent ligands and have screened this library to reveal small molecules that impair triple-negative breast cancer cell survival. Upon identifying a lead hit from this screen KEA1-97, we used activity-based protein profiling (ABPP)-based chemoproteomic platforms to identify that this compound targets lysine 72 of thioredoxin-a site previously shown to be important in protein interactions with caspase 3 to inhibit caspase 3 activity and suppress apoptosis. We show that KEA1-97 disrupts the interaction of thioredoxin with caspase 3, activates caspases, and induces apoptosis without affecting thioredoxin activity. Moreover, KEA1-97 impairs in vivo breast tumor xenograft growth. Our study showcases how the screening of covalent ligands can be coupled with ABPP platforms to identify unique anticancer lead and target pairs.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1021/acschembio.7b00711

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The compound KEA1-97, identified using an ABPP-based chemoproteomic platform, targeted the lysine-72 site of thioredoxin to disrupt its PPI with caspase-3, leading to the activation of apoptosis.

    “The compound KEA1-97, identified using a ABPP-based chemoproteomic platform, targeted the lysine-72 site of thioredoxin to disrupt its PPI with caspase-3, leading to the activation of apoptosis [70].”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. [19]Roberts AM, Miyamoto DK, Huffman TR, Bateman LA, Ives AN, Akopian D, Heslin MJ, Contreras CM, Rape M, Skibola CF, and Nomura DK (2017) Chemoproteomic Screening of Covalent Ligands Reveals UBA5 As a Novel Pancreatic Cancer Target. ACS Chem. Biol. 12, 899– 904. 28186401

Cited by

Sorted by citations

Authors
Anderson, K. E., To, M., Olzmann, J. A., & Nomura, D. K.
Affiliations
University of California, Berkeley (US)
Corresponding author
Nomura, Daniel K.
Venue
ACS Chemical Biology
Published
2017-09-13
Volume
12
Issue
10
Pages
2522-2528
ISSN
  • 1554-8929 (ISSN-L)
  • 1554-8937
OpenAlex
W2754208640
Cited by
35
References
18
Citations by year
2026: 2 · 2025: 3 · 2024: 5 · 2023: 3 · 2021: 4 · 2020: 3 · 2019: 8 · 2018: 6 · 2017: 1
FWCI
2.06
Type
journal article
Language
en
Open access
Locations
  • ACS Chemical Biology (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
Funders
  • Novartis
  • National Cancer Institute (R01 CA172667)
  • Congressionally Directed Medical Research Programs (W81XWH-15-1-10050)
  • American Cancer Society (RSG14-242-01-TBE)
  • National Institute of General Medical Sciences (R01 GM112948)
  • Novartis-Berkeley Center for Proteomics and Chemistry Technologies
Topics
  • Physical Sciences › Chemistry › Organic Chemistry › Click Chemistry and Applications
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Redox biology and oxidative stress
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
Keywords
chemoproteomics, activity-based protein profiling, thioredoxin, caspase-3, triple-negative breast cancer, apoptosis
MeSH terms
Animals, Antineoplastic Agents, Biphenyl Compounds, Breast Neoplasms, Female, Humans, Ligands, Male, Neoplasms, Experimental, Thioredoxins, Triazines, Molecular Structure, Mice, SCID, Proteomics, Cell Line, Tumor, Mice, Caspase 3

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review